Investors attending the conference

Last updated: 21 March, 2025

Albion VC, Angelini Venures, ARCH Venture Partners, ARCH Venture Partners, Avant Bio, AXA Investment Managers, Baselaunch, Biovision Ventures, BlackRock, Bluebirds Capital, Brandon Capital Partners, Cancer Research Horizons, CBG, Cell and Gene Therapy Catapult, Claret Capital Partners, CPI Enterprises, Danaher Ventures , Delin Ventures, Dementia Discovery Fund - SV Health Investors, DGB Ventures, Eli Lilly and Company, Epidarex, Eppendorf Group SE & Co. KG, Evolutia Venture Partners, First Spark Ventures, Forbion, Foresight Group, General Inception, General Inception, GL Capital, Global Brain, GSK, H Tree Capital, Healthcare Royalty, Ignite Capital Partners, Intermediate Capital Group (ICG), Inveready Asset Management, IPF Partners, ITOCHU Europe PLC, Jeito Capital, JJDC, Keles, Kerna Ventures, Kineo Finance, Lunar Ventures, M Ventures, MAKR Venture Fund, Medicines Discovery Ventures, Meltwind, Monograph, NLC Health Ventures, Norn Ventures, Novalis II General Partner BV, Octopus Ventures, OrbiMed, Oxford Science Enterprises, Panakes Partners, Parkwalk Advisers, Peppermint Venture Partners, Pioneer Group, Rosetta Capital, RYSE Asset Management, Segulah Medical Acceleration, Seventure, Sofinnova Partners, SOSV, Sound Bioventures, SPRIM Global Investments, SR One, SV Health Investors, Syncona, TechBio, The Pioneer Group, Type One Ventures, UCB Ventures, Vesalius Biocapital Partners